Assessing the Frequency of VEXAS ‐Related Canonical UBA1 Mutations in Myelodysplastic Syndrome Patients
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70210 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Hadis Soleimanzadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Blood Bank, Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shir…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Ubiquitin-Activating Enzymes, Mutation. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shiraz University of Medical Sciences.
Abstract (Originalsprache)
Objectives
Somatic mutations in the UBA1 gene cause VEXAS syndrome, which presents with inflammatory and hematological symptoms. Case studies show a strong overlap between VEXAS and myelodysplastic syndrome (MDS). Recognizing VEXAS is important for differential diagnosis in patients with both inflammation and MDS, as accurate identification guides treatment. The study focuses on determining how often canonical UBA1 mutations linked to VEXAS occur in MDS patients.
Methods
Patients diagnosed with MDS were enrolled in the study, and genomic DNA was isolated from bone marrow FFPE samples. Molecular analysis was performed using a specifically designed ARMS‐PCR approach. Additionally, protein–protein interaction (PPI) studies combined with bioinformatic analyses were carried out to explore potential links between UBA1 and pyroptosis.
Results
Among the 149 MDS patients analyzed, none exhibited high‐Variant Allele Frequency (VAF) the canonical UBA1 point mutations linked to VEXAS syndrome. PPI analysis revealed a possible association between UBA1 and the NLRP3 inflammasome component.
Conclusions
Expanding the sample size and using targeted NGS or ddPCR would improve mutation detection sensitivity and could reveal UBA1 canonical and non‐canonical variants and more accurately estimate the frequency of VEXAS‐related mutations in the MDS population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Blood Bank, Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
- Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Division of Medical Biotechnology, Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
- Hematology Research Center, Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Pathology, School of Medicine, Cancer Prevention Research Center, Seyyed Al-Shohada Hospital, Isfahan University of Medical Science, Isfahan, Iran.
ORCID-Profile: Hadis Soleimanzadeh, Mohammadjafar Sharifi
Förderung
- Shiraz University of Medical Sciences
Zitieren
APA
Soleimanzadeh, H., Sharifi, M., Shokripour, M., Saberzadeh, J., Ramzi, M., Nematollahi, P., & Nasiri, N. (2026). Assessing the Frequency of VEXAS ‐Related Canonical UBA1 Mutations in Myelodysplastic Syndrome Patients. European Journal of Haematology. https://doi.org/10.1111/ejh.70210
Vancouver
Soleimanzadeh H, Sharifi M, Shokripour M, Saberzadeh J, Ramzi M, Nematollahi P, et al. Assessing the Frequency of VEXAS ‐Related Canonical UBA1 Mutations in Myelodysplastic Syndrome Patients. European Journal of Haematology. 2026. doi:10.1111/ejh.70210
BibTeX
@article{Soleimanzadeh2026,
author = {Soleimanzadeh, Hadis and Sharifi, Mohammadjafar and Shokripour, Mansoureh and Saberzadeh, Jamileh and Ramzi, Mani and Nematollahi, Pardis and Nasiri, Nahid},
title = {Assessing the Frequency of VEXAS ‐Related Canonical UBA1 Mutations in Myelodysplastic Syndrome Patients},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70210}
}
EUVIMED